SCHEMBL22099992

SCHEMBL22099992

CC(C)(C)NC(=O)c1ccc(NC(N)=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 3/20 0.57
PEPD P12955 1/20 0.50
NPC1 O15118 4/20 0.48
ALDH1A1 P00352 1/20 0.48
USP2 O75604 1/20 0.48
LMNA P02545 2/20 0.48
MAPT P10636 2/20 0.48
HDAC3 O15379 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
RAB9A P51151 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
POLB P06746 1/20 0.47
PKM P14618 1/20 0.47
APEX1 P27695 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
TRPV1 Q8NER1 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cp1-1189 SCHEMBL154117 0.84 CACNA1B (0.61) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL15946360 0.83 LMNA (0.73) NPC1LMNAMAPTHDAC3HDAC11
SCHEMBL17865779 0.82 LMNA (0.58) LMNAMAPTPOLBSMN1; SMN2
SCHEMBL20992041 0.82 L3MBTL1 (0.68) NPC1ALDH1A1USP2LMNAMAPT
SCHEMBL1176804 0.82 USP2 (0.48) NPC1USP2LMNAMAPTHDAC3
SCHEMBL21016381 0.81 EPHX2 (0.51) LMNAMAPTSMN1; SMN2
SCHEMBL23139020 0.81 NPC1 (0.55) NPC1LMNAMAPTHDAC3HDAC11
SCHEMBL15946358 0.81 CACNA1B (0.67) NPC1ALDH1A1LMNAMAPTRAB9A
SCHEMBL21282783 0.81 HDAC3 (0.73) NPC1LMNAMAPTHDAC3HDAC11
SCHEMBL15798566 0.79 HDAC2 (0.55) KIF11PEPDNPC1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11034648-B2 Cystobactamide derivatives HELMHOLTZ-ZENTRUM FÜR (DE) 2021-06-15 US disclosed
US-20200190020-A1 NOVEL CYSTOBACTAMIDE DERIVATIVES Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11034648-B2 Cystobactamide derivatives CTH, CBS, SLC7A11 KIF11 4552/4885PEPD 66/4885NPC1 3291/4885
US-20200190020-A1 NOVEL CYSTOBACTAMIDE DERIVATIVES CTH, CBS, SLC7A11 KIF11 4394/4885PEPD 75/4885NPC1 3258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.